Heron Bay Capital Management Invests $235,000 in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL)

Heron Bay Capital Management acquired a new position in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 31,766 shares of the company’s stock, valued at approximately $235,000. Heron Bay Capital Management owned about 0.39% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission.

Separately, Rowlandmiller & PARTNERS.ADV bought a new stake in shares of Cryo-Cell International during the 4th quarter worth $107,000. 10.44% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Maxim Group lowered their price target on shares of Cryo-Cell International from $9.00 to $8.50 and set a “buy” rating for the company in a research note on Tuesday, March 4th.

Cryo-Cell International Stock Up 2.7 %

Cryo-Cell International stock opened at $6.58 on Friday. The firm has a market capitalization of $53.03 million, a price-to-earnings ratio of -6.21 and a beta of 0.53. Cryo-Cell International, Inc. has a twelve month low of $5.75 and a twelve month high of $9.50.

Cryo-Cell International Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Friday, February 14th were paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 15.20%. The ex-dividend date of this dividend was Friday, February 14th. Cryo-Cell International’s dividend payout ratio is presently -94.34%.

Cryo-Cell International Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.